Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Ervik M, Lam F, et al. Global cancer Observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2020. [Internet]. 2020 [cited 2022 Jun 3]. Available from: https://gco.iarc.fr/today/home.
   Google Scholar
• Collins LG, Haines C, Perkel R, et al. Lung cancer: diagnosis and management. afp. 2007;75:56–63.
   Google Scholar
• Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. In: Reckamp KL, editor. Lung Cancer: Treatment and Research [internet]. Cham: Springer International Publishing; 2016 p. 47–75.
   Google Scholar
• Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109–1121. doi: 10.1016/j.jtho.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–78993. doi: 10.18632/oncotarget.12587.
   PubMedGoogle Scholar
• Hsu W-H, Yang JC-H, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(suppl_1):i3–i9. doi: 10.1093/annonc/mdx702.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012;13(1):e23-31–e31. doi: 10.1016/S1470-2045(11)70129-2.
   PubMed Web of Science ®Google Scholar
• Russo A, Franchina T, Ricciardi G, et al. Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario. Int J Mol Sci. 2019;20(6):1431. doi: 10.3390/ijms20061431.
   PubMed Web of Science ®Google Scholar
• Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–S31. doi: 10.1038/onc.2009.198.
   PubMedGoogle Scholar
• Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. doi: 10.1126/science.1099314.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi: 10.1056/NEJMoa040938.
   PubMed Web of Science ®Google Scholar
• Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–179. doi: 10.1016/j.semcancer.2019.09.015.
   PubMed Web of Science ®Google Scholar
• Takeda M, Sakai K, Hayashi H, et al. Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2. Oncotarget. 2018;9(30):21132–21140. doi: 10.18632/oncotarget.24958.
   PubMedGoogle Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–184. doi: 10.1097/JTO.0b013e3182779d18.
   PubMed Web of Science ®Google Scholar
• Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR exon 20 insertions and Co-Occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560–1568. doi: 10.1016/j.jtho.2018.06.019.
   PubMed Web of Science ®Google Scholar
• Arcila ME, Nafa K, Chaft JE, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013;12(2):220–229. doi: 10.1158/1535-7163.MCT-12-0620.
   PubMed Web of Science ®Google Scholar
• Chen D, Song Z, Cheng G. Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther. 2016;9:4181–4186. doi: 10.2147/OTT.S108242.
   PubMed Web of Science ®Google Scholar
• Wu J-Y, Yu C-J, Chang Y-C, et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–3821. doi: 10.1158/1078-0432.CCR-10-3408.
   PubMed Web of Science ®Google Scholar
• Kate S, Chougule A, Joshi A, et al. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis. Lung Cancer (Auckl). 2019;10:1–10. doi: 10.2147/LCTT.S181406.
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nat Med. 2018;24(5):638–646. doi: 10.1038/s41591-018-0007-9.
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Wang Y, Sequist LV, et al. ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. J Clin Oncol. 2020;38(15_suppl):9513–9513. doi: 10.1200/JCO.2020.38.15_suppl.9513.
   Web of Science ®Google Scholar
• Floc’h N, Martin MJ, Riess JW, et al. Antitumor activity of osimertinib, an irreversible Mutant-Selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions. Mol Cancer Ther. 2018;17(5):885–896. doi: 10.1158/1535-7163.MCT-17-0758.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim TM, Kim D-W, et al. Preclinical modeling of osimertinib for NSCLC with EGFR exon 20 insertion mutations. J Thorac Oncol. 2019;14(9):1556–1566. doi: 10.1016/j.jtho.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24(13):3097–3107. doi: 10.1158/1078-0432.CCR-17-2310.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Small Cell Lung Cancer 2022 [Internet]. NCCN. 2022 [cited 2022 Jun 3]. Available from: https://www.nccn.org/guidelines.
   Google Scholar
• Huang C-Y, Ju D-T, Chang C-F, et al. A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer. Biomedicine. 2017;7(4):23. doi: 10.1051/bmdcn/2017070423.
   PubMedGoogle Scholar
• Choudhury NJ, Schoenfeld AJ, Flynn J, et al. Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res. 2021;27(10):2920–2927. doi: 10.1158/1078-0432.CCR-20-4650.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Park E, Yun C-H, et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216):216ra177. doi: 10.1126/scitranslmed.3007205.
   PubMed Web of Science ®Google Scholar
• Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 Insertion-Mutated Non-Small-Cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–3402. doi: 10.1200/JCO.21.00662.
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development, LLC. A Phase 1, first-in-human, open-label, dose escalation study of JNJ-61186372, a human bispecific EGFR and cMet antibody, in subjects with advanced non-small cell lung cancer [Internet]. clinicaltrials.gov; 2022 [cited 2022 Jun 7]. Report No.: NCT02609776. Available from: https://clinicaltrials.gov/ct2/show/NCT02609776.
   Google Scholar
• Minchom A, Viteri S, Bazhenova L, et al. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022;168:74–82. doi: 10.1016/j.lungcan.2022.03.005.
   PubMed Web of Science ®Google Scholar
• Haura EB, Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(15_suppl):9009–9009. doi: 10.1200/JCO.2019.37.15_suppl.9009.
   Web of Science ®Google Scholar
• Goto K. Development of nationwide genomic screening project (LC-SCRUM-Japan) for the establishment of cancer precision medicine. Annals Oncol. 2017;28:ix5. doi: 10.1093/annonc/mdx570.001.
   Google Scholar
• Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–764. doi: 10.1093/aje/kwv254.
   PubMed Web of Science ®Google Scholar
• Morgan CJ. Reducing bias using propensity score matching. J Nucl Cardiol. 2018;25(2):404–406. doi: 10.1007/s12350-017-1012-y.
   PubMed Web of Science ®Google Scholar
• Remon J, Hendriks LEL, Cardona AF, et al. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev. 2020;90:102105. doi: 10.1016/j.ctrv.2020.102105.
   PubMed Web of Science ®Google Scholar
• Cardona AF, Rojas L, Zatarain-Barrón ZL, et al. EGFR exon 20 insertion in lung adenocarcinomas among hispanics (geno1.2-CLICaP). Lung Cancer. 2018;125:265–272. doi: 10.1016/j.lungcan.2018.10.007.
   PubMed Web of Science ®Google Scholar
• Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186–194. doi: 10.1016/j.lungcan.2020.03.014.
   PubMed Web of Science ®Google Scholar
• Hirose T, Ikegami M, Endo M, et al. Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer. 2021;152:135–142. doi: 10.1016/j.lungcan.2020.12.023.
   PubMed Web of Science ®Google Scholar
• Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Sig Transduct Target Ther. 2019;4(1):10. doi: 10.1038/s41392-019-0038-9.
   PubMedGoogle Scholar
• Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol. 2021;16(5):764–773. doi: 10.1016/j.jtho.2020.12.002.
   PubMed Web of Science ®Google Scholar
• Johnson&Johnson. Treatment with RYBREVANT® (amivantamab-vmjw) plus chemotherapy resulted in statistically significant and clinically meaningful improvement in progression-free survival in patients with newly diagnosed EGFR exon 20 insertion mutation-positive non-small cell lung cancer. [cited Aug 2023]. Available from: https://www.jnj.com/treatment-with-rybrevant-amivantamab-vmjw-plus-chemotherapy-resulted-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer
   Google Scholar